Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1992 Sep-Dec;114(9-12):300-3.

[Diabetic maculopathy]

[Article in Croatian]
Affiliations
  • PMID: 1343138
Review

[Diabetic maculopathy]

[Article in Croatian]
M Ivanisević. Lijec Vjesn. 1992 Sep-Dec.

Abstract

Diabetic maculopathy is a leading cause of decreased vision from diabetic retinopathy. It is usually encountered in older non-insulin-dependent diabetics with mainly nonproliferative diabetic retinopathy. Diabetic maculopathy can be divided into three main types, exudative (focal), edematous (diffuse or cystoid) and ischemic. Many reports do not distinguish among the various forms of diabetic maculopathy, but only discuss the diabetic macular edema which is the first and the most dominant sign of diabetic maculopathy. No drug therapy has shown to have therapeutic effect in diabetic maculopathy. Photocoagulation, although, symptomatic, is of benefit in edematous and exudative diabetic maculopathy, in the sense that it produces an improvement or maintenance of the clinical picture and visual acuity. Thereby, good glycemic control and the treatment of potential systemic diseases such as hypertension and renal failure are recommended. Photocoagulation is focal, applied directly at microaneurysms and areas of fluorescein leakages and in a "grid" pattern for diffuse macular edema. Fluorescein angiography is necessary to discover the areas of fluorescein leakage, and is helpful in the follow-up of treatment results.

PubMed Disclaimer

LinkOut - more resources